Monoclonal antibodies (MABs) – A quick guide
Monoclonal antibodies also are known as MABs/moAb are cells derived by cell division from a single ancestral cell. These monoclonal antibodies are molecules produced in a laboratory that are developed to serve as a substitute antibodies that are capable of mimicking, enhancing or restoring the immune system’s attack on diseases such as cancer. The monoclonal antibodies are produced in such a way that they bind to antigens promoting the immune system attacks on diseased cells.
Monoclonal Antibodies Market Size
Monoclonal antibodies are now used as a biological therapy to treat some types of cancer and these antibodies are artificially produced against a specific antigen to their target antigens. The laboratory production of monoclonal antibodies attained commercial status with the first therapeutic monoclonal antibody product in 1986. From then on, the monoclonal antibody market size grew exponentially with the present monoclonal antibodies market value estimated to worth $ 86647.561 million in 2016 and expected to reach $ 138.6 billion by the end of 2024.
Download a free sample report: http://www.marketdataforecast.com/market-reports/global-monoclonal-antibodies-market-1184/request-sample
Increasing Research and Development activities pertaining to the development of therapeutic antibodies to provide target therapies, depending upon the response of each individual in a different manner to a particular treatment is creating a new demand in the global monoclonal antibodies market. The related advantages of using mAbs for therapeutic purposes with fewer adverse effects, homogeneity and large-scale production are contributing to towards growth of global mAbs market.
Global monoclonal antibodies market – An insight
According to the monoclonal antibodies market forecast, the human based global mAbs is predicted to grow at a lucrative CAGR of 5.7% that may reach to $ 1121.75 million by the end of 2021. Every year, new products of monoclonal antibodies are being introduced, approved and as such in 2014 about 47 monoclonal antibodies products have been approved in the United States and in Europe for the treatment of a variety of diseases with many of these products having been approved for other global mabs market.
The growing awareness levels among the physicians, patients about the applications of monoclonal antibodies therapy is further contributing to monoclonal antibody market growth. It is estimated that by the end of 2020 there would be more than 70 new monoclonal antibody products with a combined sales reaching nearly $ 125 billion.
The government initiatives in the form of government funding such as National Natural Science Foundation and the National Basic Research Program of China is offering financial support to universities and enterprises engaged in the conducting mAb research and development.
In addition, the surging incidence of cancer is the key contributing factor towards the growth of monoclonal antibodies market size. Regional wise North America occupies the maximum share in 2015 due to the presence of well-established healthcare infrastructure and increasing government funding for cancer research and technology development of therapeutic products. The Asia-Pacific region is the other region that is expected to exhibit a considerable growth due to the rising economic growth of China and India.
Categorization of Monoclonal Antibodies Market
The global mAbs market is broadly divided or categorized into four categories with each of the Monoclonal antibody products falling under these categories as shown in the tabulated format herein below-
Research Institute and Diagnostic Laboratories
|Medical and Experimental|
Humanized mAbs in the overall monoclonal antibodies market share account for the largest revenue generator for the market because of the wide adoption in the treatment of various diseases that include cancer and inflammatory diseases. The potential growth driver for this segment can be attributed to the incorporation of advanced technology such as the phage or yeast display and transgenic mice for their generation. The Adalimumab was the first human antibody that was approved by US FDA in 2003 under this category. The key players or companies contributing to the growth of global mAbs market or industry include Novartis AG, Pfizer Inc, GlaxoSmithKline plc, Daiichi Sankyo Company, Abbott, AstraZeneca, etc.
For the past five years, the global sales of monoclonal antibody products have grown faster when compared with other biopharmaceutical products. In the coming years, the introduction of biosimilars in these markets is expected to have a very large impact on the global sales of monoclonal antibody products.